Transurethral resection of the prostate (TURP) is effective for treating benign prostatic obstruction, but it is not reliable for detecting cancer, data show.

A short-term follow-up study shows that GreenLight HPS laser photoselective vaporization prostatectomy (PVP) is safe and effective for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH), according to a report in the Journal of Endourology (2008;22:2341-2347).

Transurethral ethanol injection may be a treatment options for some men with benign prostatic hyperplasia (BPH), long-term study data suggest.

Use of 5-α reductase inhibitors for benign prostatic hyperplasia (BPH) does not significantly increase the risk of hip fracture, researchers conclude.

Benign prostatic hyperplasia (BPH) is reported significantly less often among blacks than whites, according to a study of 21,949 men. Despite an apparently lower prevalence of BPH, blacks with BPH are more likely than whites to have had surgery for the condition.

CELECOXIB IS effective for treating BPH patients with refractory nocturia, researchers in Iran reported in Urology (2008; online ahead of print).

LONG-TERM treatment with finasteride either alone or in combination with doxazosin is associated with clinically significant reductions in total prostate volume in patients with lower urinary tract symptoms (LUTS) and BPH, regardless of baseline prostate size, data show.

ORLANDO—Elderly men with moderate or severe lower urinary tract symptoms (LUTS) are at significantly greater risk for falls, and the risk dramatically increases as the symptoms worsen, data show.

GlaxoSmithKline has received a new indication for Avodart (dutasteride) in combination with the alpha blocker tamsulosin for the treatment of symptomatic enlarged prostate, a disease affecting half of all men over age 50.

Celecoxib is effective for treating BPH patients with refractory nocturia, researchers in Iran reported in Urology (2008; online ahead of print).